biotechnology | Science and Enterprise

Start-up companies working in artificial intelligence scored sizeable increases in venture financing, and were high… https://t.co/oLdLmHGz1M
about 18 hours ago
New post on Science and Enterprise: Venture Funds, Mergers in A.I. Up Sharply in 2018 https://t.co/rimak87tjS #Science #Business
about 18 hours ago
Wish it weren't needed, but ... https://t.co/SZAb2GO2vz
about 3 days ago
The Edelman public relations agency released results of a survey earlier this month gauging the public's awareness… https://t.co/XaxxGJOYQl
about 3 days ago
New post on Science and Enterprise: Infographic – Public, Tech Execs Differ on A.I. Use https://t.co/cvVj3IyCR0 #Science #Business
about 3 days ago

Gene Editing Deactivates Cause of T-Cell Side Effects

By Alan, on February 26th, 2019%

A biotechnology company developing engineered T-cells as treatments for cancer, used gene editing to deactivate a likely cause of serious adverse effects from its therapies. . . . → Read More: Gene Editing Deactivates Cause of T-Cell Side Effects

Gene Therapy Company Acquired in $4.3B Deal

By Alan, on February 25th, 2019%

Spark Therapeutics, a biotechnology company that pioneered gene therapies, is being acquired by drug maker Roche Group in a deal valued at $4.3 billion. . . . → Read More: Gene Therapy Company Acquired in $4.3B Deal

Start-Up Raises $10.5M for Precision Immunotherapies

By Alan, on February 21st, 2019%

A new biotechnology enterprise developing personalized treatments that harness the immune system to treat cancer is raising $10.5 million in its first venture funding round. . . . → Read More: Start-Up Raises $10.5M for Precision Immunotherapies

Targeted Chemo Seen Benefiting Breast Cancer Patients

By Alan, on February 21st, 2019%

A clinical trial shows a treatment combining an antibody and chemotherapy drug invokes a response and longer survival time in many patients with metastatic triple-negative breast cancer. . . . → Read More: Targeted Chemo Seen Benefiting Breast Cancer Patients

Trial Shows RNA Therapy Safe for Diabetes

By Alan, on February 20th, 2019%

Results from a clinical trial show a new drug with synthetic messenger RNA is safe for people with diabetes, and has the potential to promote new blood vessel growth. . . . → Read More: Trial Shows RNA Therapy Safe for Diabetes

High-Speed Screens, A.I., Boost Nanoscale Medicines

By Alan, on February 20th, 2019%

Biomedical engineers are using high-throughput screening techniques and machine learning to speed and improve the design of new drugs based on nanoscale particles. . . . → Read More: High-Speed Screens, A.I., Boost Nanoscale Medicines

Stem Cell Genes Edited to Avoid Immune Rejection

By Alan, on February 19th, 2019%

A new study shows editing the genomes of adult stem cells can avoid their rejection by the immune system when implanted in lab mice other than the stem cell donor. . . . → Read More: Stem Cell Genes Edited to Avoid Immune Rejection

Genetic Engineering, Silencing Boost Plant Output

By Alan, on February 18th, 2019%

An agricultural research lab uses genetic engineering and gene silencing to produce crop plants that increase their yields by more than 40 percent. . . . → Read More: Genetic Engineering, Silencing Boost Plant Output

FDA Approves 25 Precision Meds in 2018

By Alan, on February 13th, 2019%

An organization advocating for medicines addressing a person’s unique chemical composition rather than disease symptoms says U.S. regulators approved 25 of those drugs in 2018. . . . → Read More: FDA Approves 25 Precision Meds in 2018

UC-Berkeley to Get New Crispr Patent

By Alan, on February 11th, 2019%

University of California in Berkeley will soon receive a new patent for its development of the genome editing process known as Crispr, the latest round in a years-long dispute. . . . → Read More: UC-Berkeley to Get New Crispr Patent

Science & Enterprise subscription

Specials

Follow us on Twitter

Guest Posts

Please share Science & Enterprise